Anixa Biosciences (ANIX) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OnKure Therapeutics (OKUR) has outperformed Anixa Biosciences (ANIX) over the past year, losing 24.3% versus a loss of 34.5%. Over five years, ANIX leads with a -33.7% price change compared with -96.4% for OKUR. Anixa Biosciences is the larger company by market cap ($101.2 million vs $93.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | OKUR |
|---|---|---|
| Share price | $2.91 | $2.30 |
| Market cap | $101.16M | $93.14M |
| 1-day change | -1.36% | -2.13% |
| YTD return | -6.73% | -20.69% |
| 1-year return | -34.46% | -24.34% |
| 5-year return | -33.71% | -96.43% |
| EPS (TTM) | $-0.32 | $-3.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $5.38 |
| 52-week low | $2.32 | $2.13 |
| Distance from 52-week high | -46.70% | -57.25% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +235.05% | +573.91% |
| Average volume | 302.95K | 216.96K |
| Shares outstanding | 34.76M | 40.50M |
| Employees | 4 | 45 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKUR has outperformed ANIX by 10.1 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Healthcare · Biotechnology · 4 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Healthcare · Biotechnology · 45 employees
ANIX vs OKUR FAQ
Which is bigger, Anixa Biosciences or OnKure Therapeutics?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $101.16M compared with $93.14M for OnKure Therapeutics (OKUR).
Which stock has performed better over the past year, ANIX or OKUR?
OKUR returned -24.34% over the past 12 months, compared with -34.46% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and OnKure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.